A share price of Arcturus Therapeutics Holdings Inc [ARCT] is currently trading at $7.27, down -6.44%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARCT shares have lost -16.63% over the last week, with a monthly amount drifted -66.54%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] stock has seen the most recent analyst activity on October 24, 2025, when H.C. Wainwright downgraded its rating to a Neutral but kept the price target unchanged to $12 for it. Previously, Citigroup downgraded its rating to Neutral on October 23, 2025, and kept the price target unchanged to $12. On October 22, 2025, downgrade downgraded it’s rating to Neutral. Scotiabank initiated its recommendation with a Sector Outperform and recommended $32 as its price target on May 28, 2025. BTIG Research started tracking with a Buy rating for this stock on January 28, 2025, and assigned it a price target of $41. In a note dated August 12, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $70 on this stock.
Arcturus Therapeutics Holdings Inc experienced fluctuations in its stock price throughout the past year between $7.76 and $24.17. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $7.27 at the most recent close of the market. An investor can expect a potential return of 491.47% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
Trailing Twelve Months sales for Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] were 85.14M which represents -63.54% decline. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.85%, Pretax Profit Margin comes in at -0.72%, and Net Profit Margin reading is -0.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.22 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.14 points at the first support level, and at 7.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.53, and for the 2nd resistance point, it is at 7.78.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] is 7.86. Also, the Quick Ratio is 7.86, while the Cash Ratio stands at 5.69. Considering the valuation of this stock, the price to sales ratio is 2.43, the price to book ratio is 0.88.
